All data are based on the daily closing price as of November 10, 2025
h
Hanmi Pharm. Co.
128940.KO
305.17 USD
4.26
+1.42%
Overview
Last close
305.17 usd
Market cap
3.87B usd
52 week high
317.69 usd
52 week low
146.58 usd
Target price
298.63 usd
Valuation
P/E
N/A
Forward P/E
N/A
Price/Sales
3.7599
Price/Book Value
3.9831
Enterprise Value
3.27B usd
EV/Revenue
3.2385
EV/EBITDA
18.0117
Key financials
Revenue TTM
1.03B usd
Gross Profit TTM
566.86M usd
EBITDA TTM
201.16M usd
Earnings per Share
N/A usd
Dividend
0.86 usd
Total assets
1.45B usd
Net debt
259.10M usd
About
Hanmi Pharm. Co., Ltd., a biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally. It focuses on research areas with high unmet medical needs, including obesity, metabolism, oncology, and rare diseases. The company's products include Gugutams, a urological combination therapy combining two active ingredients: tamsulosin, a treatment for Obstructive Prostatic Growth (OPG), and tadalafil, a treatment for erectile dysfunction (ED). The company has a research collaboration with MEDIC Life Sciences Inc. to identify cancer biomarkers. The company was founded in 1973 and is based in Hwaseong-si, South Korea.